Search Medical Condition
Please enter condition
Please choose location

Adazi, Latvia Clinical Trials

A listing of Adazi, Latvia clinical trials actively recruiting patients volunteers.

RESULTS

Found (24) clinical trials

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

The purpose of the study is to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue and predictability of disease flares in patients with axial spondyloarthritis who have an inadequate response to prior ...

Phase

5.16 miles

Learn More »

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

Phase

7.68 miles

Learn More »

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in the ...

Phase

7.68 miles

Learn More »

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)

This Phase III, double-blind, placebo and active comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active UC who are naIve to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

Phase

7.68 miles

Learn More »

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Up to 34 weeks, including a Screening Phase of up to 2 weeks, a 2 week Run-In Phase, a 26-week double-blind Treatment Period and a 4-week post-treatment Follow-up Period to collect safety information.

Phase

7.68 miles

Learn More »

Diagnosis of Gastric Lesions With Na-nose

Number of patients that will have a definitive diagnosis and Alveolar exhaled breath samples collected from individuals with Tedlar bags (Keika Ventures, LLC) after endoscopy.. Two breath samples were collected from each person tested. Two-bed sorption tubes filled with the following sorbents were used as traps for sample collection with ...

Phase N/A

7.68 miles

Learn More »

Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

To compare all-cause mortality at Day 14 in participants receiving S-649266 with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP) caused by Gram-negative pathogens.

Phase

7.68 miles

Learn More »

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

The study consists of a single dose course of IGIV-C treatment followed by 28-days of post-infusion assessments. The total duration of study participation for each subject is up to 28 2 days. Approximately 50 subjects, ages 18 or greater, are planned to be enrolled in the study and receive a ...

Phase

8.02 miles

Learn More »

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

This is a randomized, double-blind, double-dummy, active comparator-controlled, parallel-group, multicenter study with variable treatment duration in approximately 900 patients with relapsing MS. The maximal treatment duration in the study for an individual patient will be 2.5 years. Eligible patients will be randomized to receive either experimental ofatumumab subcutaneous (sc) injections ...

Phase

8.02 miles

Learn More »

Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients

There is a screening period of up to 6 weeks, a treatment period of a minimum of 52 weeks and a maximum of approximately up to 3 years after last patient is randomized, and a post-treatment follow-up period of 4 weeks. A total of up to 900 patients will be ...

Phase

8.02 miles

Learn More »